William Dezarn to Yttrium Radioisotopes
This is a "connection" page, showing publications William Dezarn has written about Yttrium Radioisotopes.
Connection Strength
1.945
-
Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, Kennedy AS, Nag S, Sarfaraz M, Sehgal V, Selwyn R, Stabin MG, Thomadsen BR, Williams LE, Salem R. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011 Aug; 38(8):4824-45.
Score: 0.390
-
Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):631-7.
Score: 0.346
-
Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, Beny A, Dezarn WA. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009 Jul; 27(6):682-90.
Score: 0.338
-
Dezarn WA. Quality assurance issues for therapeutic application of radioactive microspheres. Int J Radiat Oncol Biol Phys. 2008; 71(1 Suppl):S147-51.
Score: 0.304
-
Dezarn WA, Kennedy AS. Resin 90Y microsphere activity measurements for liver brachytherapy. Med Phys. 2007 Jun; 34(6):1896-900.
Score: 0.292
-
Dezarn WA. Regarding "PET/CT Imaging Characteristics After Radioembolization of Hepatic Metastasis from Breast Cancer". Cardiovasc Intervent Radiol. 2020 03; 43(3):520.
Score: 0.175
-
Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009 Aug 01; 74(5):1494-500.
Score: 0.082
-
Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007 Mar 14; 5:15.
Score: 0.018